PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS
The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): (I) wherein R1, R2, R3, R4, R4' and R5 are as defined in the description and claims; and compounds or pharmaceutically acceptable salts thereof of formulas (II), (IIa), (IIb), (IIc), and (III) having...
Saved in:
Main Authors | , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
17.12.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): (I) wherein R1, R2, R3, R4, R4' and R5 are as defined in the description and claims; and compounds or pharmaceutically acceptable salts thereof of formulas (II), (IIa), (IIb), (IIc), and (III) having mTOR kinase inhibitor activity. The invention also relates to pharmaceutical compositions which include a compound of formula (I), (II), (IIa), (IIb), (IIc), or (III) or a pharmaceutically acceptable salt thereof, and to the use of a compound of formula (I), (II), (IIa), (IIb), (IIc), or (III), or a pharmaceutically acceptable salt thereof in therapy, including in the treatment of a disease or condition for which an mTOR kinase inhibitor activity is indicated, and in particular the treatment of idiopathic pulmonary fibrosis.
L'invention concerne des composés ou des sels pharmaceutiquement acceptables de ceux-ci de formule (I) : (I) Dans laquelle R1, R2, R3, R4, R4' et R5 sont tels que définis dans la description et les revendications ; et des composés ou des sels pharmaceutiquement acceptables de ceux-ci de formules (II), (IIa), (IIb), (IIc) et (III) ayant une activité inhibitrice de la kinase mTOR. L'invention concerne également des compositions pharmaceutiques comprenant un composé de formule (I), (II), (IIa), (IIb), (IIc) or (III) ou un sel pharmaceutiquement acceptable de celui-ci, et l'utilisation d'un composé de formule (I), (II), (IIa), (IIb), (IIc) ou (III) ou d'un sel pharmaceutiquement acceptable de celui-ci en thérapie, notamment dans le traitement d'une maladie ou d'une affection dans laquelle une activité d'inhibition d'une kinase mTOR est indiquée, et en particulier dans le traitement de la fibrose pulmonaire idiopathique. |
---|---|
Bibliography: | Application Number: WO2020EP66155 |